Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of akebiasaponin D in preparing medicines for treating and preventing fatty liver and related diseases

A technology of akebia saponin and fatty liver, which is applied in the fields of application, metabolic diseases, food preparation, etc., and can solve the problems of unproven curative effect, exact curative effect to be confirmed, lack of etc.

Inactive Publication Date: 2012-05-23
GENERAL HOSPITAL OF THE SECOND ARTILLERY OF CHINESE PLA
View PDF5 Cites 7 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

③Ursodeoxycholic acid is a commonly used drug for the treatment of fatty liver in clinical practice. It was once considered to be effective in reducing liver fat content, but its efficacy has not been confirmed by two years of randomized double-blind trials.
④Antioxidants such as reduced glutathione, silymarin, vitamin E, taurine, etc. have a certain effect of reducing enzymes and protecting the liver, participate in fat metabolism in the liver, reduce liver inflammation, promote the recovery of damaged liver cells, and help Treats fatty liver and can reduce induced fibrosis, but its exact efficacy remains to be proven
⑤ Studies have shown that phytoestrogens can effectively regulate lipid metabolism in ovariectomized rats. This type of drug has both estrogen-like effects and no estrogen-like side effects, and has a protective effect on the liver. There are research reports on body composition and compound prescriptions, but no phytoestrogens have been registered as drugs for the treatment of fatty liver associated with hormone deficiency
[0010] At present, there is no report on the application of Dipsacus and aketoside D in the preparation of medicines and / or health products for the treatment and prevention of fatty liver and related diseases

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of akebiasaponin D in preparing medicines for treating and preventing fatty liver and related diseases
  • Application of akebiasaponin D in preparing medicines for treating and preventing fatty liver and related diseases
  • Application of akebiasaponin D in preparing medicines for treating and preventing fatty liver and related diseases

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0020] Example 1 Separation and purification of aketoside D

[0021] According to the research results of extraction process optimization, take 5.0kg of Dipsacus chuanxiong medicinal material decoction pieces, add 70% ethanol to heat and reflux to extract twice, the amount of extraction solvent is 10 times (V / W) of the raw medicinal material each time, and the extraction time is 2 times each time. hours, combined the two extracts, recovered ethanol under reduced pressure, and obtained aketoside D transfer rate of 93%. By screening the experimental results, AB-8 macroporous adsorption resin was selected as the rough step separation method to enrich the crude product of aketoside D. The AB-8 macroporous adsorption resin column was 10cm in diameter x 65cm in length, and the weight ratio of resin dosage to medicinal material It is 1:1. Dilute the above-mentioned concentrated drug solution with water to a solid content of 8%, load the sample, wash with 3 column volumes of water, r...

Embodiment 2

[0022] Example 2 Preparation of aketoside D

[0023] Test 1. Preparation of Aketoside D Injection

[0024] Prescription 1: Akebia saponin D 1000mg, solubilizer F68 20mg, cosolvent propylene glycol 60mg, antioxidant sodium sulfite 30mg. Adjust the isotonicity with anhydrous glucose, adjust the pH value to 7 with buffer salt, and add redistilled water to 150mL.

[0025] Prescription 2: Akebia saponin D 1000mg, solubilizer F68 25mg, HP-β-cyclodextrin 2000mg, antioxidant sodium sulfite 50mg. Dissolve the prescribed amount of HP-β-cyclodextrin in 40mL of ethanol at 600r.min -1 Add aketoside D powder under stirring, continue to stir for 2 hours, and set aside; take sodium bisulfite and F68 and add 50mL aqueous solution to dissolve, and inject aketoside D's HP-β-cyclodextrin ethanol solution under stirring until aketoside D was completely dissolved, then pre-frozen at -60°C, and dried in vacuum to obtain an off-white loose freeze-dried powder.

[0026] Test 2. Preparation of Aket...

Embodiment 3

[0029] Example 3 Aketoside D inhibits the growth and proliferation of adipocytes

[0030] Material: Akebia saponin D content 98% (prepared by the Pharmacy Department of the Second Artillery General Hospital, batch number: 20090926; dissolved in sterilized distilled water, refrigerated and stored at 4°C for later use, when dosing, use DMEM / Ham's F12 containing 10% fetal bovine serum culture medium diluted to the desired concentration). Mouse preadipocyte 3T3-L1 (Cell Center, Chinese Academy of Medical Sciences). DMEM / Ham's F12 medium (Gibco); fetal calf serum (FCS, Gibco); newborn calf serum (NCS, Gibco); dimethyl sulfoxide (DMSO, Sigma); tetramethylazozolium salt (MTT, Sigma ); propidium iodide (PI, Sigma); TritonX-100 (Sigma); trypsin (AMRESCO); 3-isobutyl-1-methylxanthine (IBMX, Sigma); dexamethasone (Dex, Sigma ); Insulin (Insulin, Sigma). LS-1F ultra-clean bench (Shanghai Thorpe Instruments); 4950E CO2 cell incubator (USA, NUNR); AU640 inverted microscope (Olympus); 550...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention aims at providing a new application of akebiasaponin D, particularly an application of akebiasaponin D in preparing medicines and / or health products for treating and preventing fatty liver and related diseases by using akebiasaponin D as an active component, wherein, the fatty liver comprises alcoholic fatty liver and non-alcoholic fatty liver, and fatty liver and hyperlipidemia due to decreased estrogen levels, and the related diseases comprise fatty liver with lipid metabolism abnormality, hormone level disorder, fatty liver with dyslipidemia, steatohepatitis, liver cirrhosis, and the like. Studies of pharmacology, pharmaceutical effect and toxicology prove that the medicines and / or health products prepared by using akebiasaponin D as the active component have remarkable effects on treating and preventing fatty liver and fatty liver with hyperlipidemia, diabete and other related diseases, and have tiny toxicity.

Description

technical field [0001] The present invention relates to a new application of aketoside D, especially in the preparation of medicines and / or health products for treating and preventing fatty liver and fatty liver with hyperlipidemia and other related diseases. Background technique [0002] Fatty liver disease (FLD), referred to as fatty liver, refers to liver fat metabolism disorder caused by various factors, and the dynamic balance of lipid substances is out of balance, resulting in excessive fat accumulation in liver cells and diffuse fatty infiltration in the liver. (steatosis) and a series of pathophysiological changes in a clinicopathological syndrome, which includes alcoholic fatty liver and non-alcoholic fatty liver. Fatty liver is a frequent and common lifestyle disease among people in today's society. In recent years, the prevalence of fatty liver at home and abroad has gradually increased, and it is showing a trend of younger age. According to epidemiological survey...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/704A61P1/16A61P3/06A61P5/30A23L1/30
Inventor 刘丽宏雷宁蓝苑元张晓菲罗恋王玲李超吴诚
Owner GENERAL HOSPITAL OF THE SECOND ARTILLERY OF CHINESE PLA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com